The first sign of multiple myeloma varies by person and may not occur until a later stage of the disease. Learn how to ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

Giving patients a whole-body MRI scan can detect minuscule amounts of myeloma, also known as minimal residue disease, even when traditional tests showed no signs of cancer, researchers found. Usual ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process. While this rare blood cancer can cause many complications, it can't be ...

Multiple myeloma is a cancer of plasma cells—cells that live inside your bone marrow and play an important role in your immune system. These plasma cells normally make antibodies that fight ...

—Arcellx’s BCMA-targeting cell therapy, anito-cel, posted Phase 2 results in multiple myeloma that analysts say are comparable to Carvykti from partners Legend Biotech and Johnson & Johnson.

What this means, he explained, is that in myeloma causes alterations that affect multiple inflammatory pathways, including for CD4 and CD8 T cells, “the 2 cell types that we are most interested ...

Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell therapy targeting the “enigmatic” GPRC5D antigen which generated remissions in 70.6% of patients ...

The CAR T-therapies Abecma and Carvykti may now be used in earlier lines of treatment for multiple myeloma. The expanded FDA approvals makes these cell therapies more accessible to more patients ...